Athira Pharma Inc. has announced a private placement agreement with a group of investors to raise approximately $90 million through the sale of common stock and warrants. The offering consists of about 5.4 million shares of common stock, pre-funded warrants to purchase approximately 8.8 million shares, and accompanying Series A and Series B common warrants to purchase a total of over 44 million shares at exercise prices of $6.35 and $7.62 per share, respectively. The financing was co-led by Commodore Capital, Perceptive Advisors, and TCGX, with additional participation from several institutional investors. Athira intends to use the net proceeds to fund the development of lasofoxifene for treatment-resistant metastatic breast cancer, advance other clinical assets, and for general corporate purposes. The securities offered have not been registered under the Securities Act of 1933 and may not be sold in the United States without registration or an applicable exemption. The company expects the financing to support its operations through key clinical milestones and provide runway into 2028.